REPLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Replimune Group, Inc.
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$11.05+0.19 (+1.75%)
Close on Oct 19, 2026
- Market cap
- $1.07B
- P/E (TTM)
- –
- Dividend yield
- –
Replimune statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Replimune | Industry median |
|---|---|---|
| Market Cap | $1.04B | $166.30M |
| Enterprise Value | $929.91M | $88.19M |
| PB Ratio | 9.85 | 2.03 |
| P/TBV Ratio | 9.85 | 2.29 |
Income (trailing twelve months)
| Measure | Replimune | Industry median |
|---|---|---|
| Operating Income | -$297.74M | -$21.40M |
| Net Income | -$297.01M | -$22.46M |
| EBITDA | -$294.44M | -$16.91M |
| EPS (Diluted) | -$3.16 | -$0.83 |
Returns
| Measure | Replimune | Industry median |
|---|---|---|
| Return on Equity (ROE) | -134.3% | -53.2% |
| Return on Assets (ROA) | -82.3% | -40.9% |
| Return on Capital Employed (ROCE) | -139.1% | -38.1% |
Balance sheet
| Measure | Replimune | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $195.33M | $61.43M |
| Total Debt | $84.11M | $118.52M |
| Net Cash (Debt) | $111.21M | $15.35M |
| Net Cash Per Share | $1.18 | $0.66 |
| Equity (Book Value) | $105.65M | $49.09M |
| Book Value Per Share | $1.12 | $1.37 |
| Tangible Book Value | $105.65M | $23.52M |
| Working Capital | $162.40M | $76.81M |
Financial position
| Measure | Replimune | Industry median |
|---|---|---|
| Current Ratio | 5.23 | 3.34 |
| Quick Ratio | 5.09 | 2.44 |
| Debt / Equity | 0.80 | 0.52 |
| Interest Coverage | -37.68 | -6.26 |
Cash flow (trailing twelve months)
| Measure | Replimune | Industry median |
|---|---|---|
| Operating Cash Flow | -$279.06M | -$12.35M |
| Capital Expenditures | -$1.49M | -$1.08M |
| Free Cash Flow | -$280.55M | -$20.22M |
| FCF Per Share | -$2.98 | -$0.42 |
Efficiency
| Measure | Replimune | Industry median |
|---|---|---|
| Profits Per Employee | -$638.74K | -$703.34K |
| Employee Count | 465 | 74 |
Dividends and yields
| Measure | Replimune | Industry median |
|---|---|---|
| Earnings Yield | -28.5% | -23.3% |
| FCF Yield | -26.9% | -8.72% |
Shares
| Measure | Replimune | Industry median |
|---|---|---|
| Shares Outstanding | 94,219,600 | 58,127,000 |
| Shares Change (YoY) | 9.31% | 10.9% |
| Shares Change (QoQ) | 1.53% | 0.54% |
| Float | 80,338,200 | 49,136,700 |
| Shares Held by Insiders | 14.7% | 11.6% |
| Shares Held by Institutions | 101.3% | 59.4% |
Scores
| Measure | Replimune | Industry median |
|---|---|---|
| Altman Z-Score | -6.25 | -0.22 |
| Piotroski F-Score | 0 | 4 |
Calculated by StockData from Replimune's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.